Literature DB >> 31498126

Identification of a Novel Deep Intronic Mutation in CAPN3 Presenting a Promising Target for Therapeutic Splice Modulation.

Ying Hu1, Payam Mohassel1, Sandra Donkervoort1, Pomi Yun1, Véronique Bolduc1, Daniel Ezzo1,2, Jahannaz Dastgir1,3, Jamie L Marshall4,5, Monkol Lek4,5,6, Daniel G MacArthur4,5, A Reghan Foley1, Carsten G Bönnemann1.   

Abstract

Calpainopathy, also known as limb girdle muscular dystrophy (LGMD) type 2A (LGMD2A) or LGMD R1 Calpain3-related, is one of the most common genetically characterized forms of limb-girdle muscular dystrophy with a wide range of phenotypic severity. We evaluated a consanguineous family with a clinical phenotype consistent with calpainopathy in whom conventional sequencing did not detect any mutations in the CAPN3 gene. Using whole exome sequencing paired with haplotype analysis, we identified a homozygous deep intronic single base pair deletion in CAPN3 (c.946-29delT). Familial segregation studies were consistent with recessive inheritance. Immunoblotting of muscle tissue from the patient showed complete absence of calpain 3. In silico analysis predicted the deletion to disrupt the branch point and subsequently alter splicing of exon 7. Studies of patient fibroblasts and muscle tissue confirmed altered splicing, resulting in an inclusion of a 389-bp intronic sequence upstream of exon 7, originating from a cryptic splice acceptor site in intron 6. This out-of-frame insertion results in a premature stop codon, leading to an apparent absence of protein likely due to degradation of the transcript via nonsense-mediated decay. We then designed phosphorodiamidate morpholino oligomers (PMOs) as splice modulators to block the new splice acceptor site. This approach successfully prevented the aberrant splicing - reverting the majority of the splice to the wildtype transcript. These results confirm the pathogenicity of this novel deep intronic mutation and provide a mutation-specific therapeutic strategy. Thus, deep intronic mutations in CAPN3 may be pathogenic and should be considered in the appropriate clinical setting. The identification of mutations which may be missed by traditional Sanger sequencing is essential as they may be excellent targets for individualized therapeutic strategies using RNA-directed splice modulation.

Entities:  

Keywords:  Calpainopathy; LGMD2A; deep intronic mutation; phosphorodiamidate morpholino oligomer (PMO)

Mesh:

Substances:

Year:  2019        PMID: 31498126      PMCID: PMC7522968          DOI: 10.3233/JND-190414

Source DB:  PubMed          Journal:  J Neuromuscul Dis


  23 in total

Review 1.  Protein and genetic diagnosis of limb girdle muscular dystrophy type 2A: The yield and the pitfalls.

Authors:  Marina Fanin; Corrado Angelini
Journal:  Muscle Nerve       Date:  2015-05-29       Impact factor: 3.217

Review 2.  The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and Opportunities.

Authors:  Jessica X Chong; Kati J Buckingham; Shalini N Jhangiani; Corinne Boehm; Nara Sobreira; Joshua D Smith; Tanya M Harrell; Margaret J McMillin; Wojciech Wiszniewski; Tomasz Gambin; Zeynep H Coban Akdemir; Kimberly Doheny; Alan F Scott; Dimitri Avramopoulos; Aravinda Chakravarti; Julie Hoover-Fong; Debra Mathews; P Dane Witmer; Hua Ling; Kurt Hetrick; Lee Watkins; Karynne E Patterson; Frederic Reinier; Elizabeth Blue; Donna Muzny; Martin Kircher; Kaya Bilguvar; Francesc López-Giráldez; V Reid Sutton; Holly K Tabor; Suzanne M Leal; Murat Gunel; Shrikant Mane; Richard A Gibbs; Eric Boerwinkle; Ada Hamosh; Jay Shendure; James R Lupski; Richard P Lifton; David Valle; Deborah A Nickerson; Michael J Bamshad
Journal:  Am J Hum Genet       Date:  2015-07-09       Impact factor: 11.025

3.  Improving genetic diagnosis in Mendelian disease with transcriptome sequencing.

Authors:  Beryl B Cummings; Jamie L Marshall; Taru Tukiainen; Monkol Lek; Sandra Donkervoort; A Reghan Foley; Veronique Bolduc; Leigh B Waddell; Sarah A Sandaradura; Gina L O'Grady; Elicia Estrella; Hemakumar M Reddy; Fengmei Zhao; Ben Weisburd; Konrad J Karczewski; Anne H O'Donnell-Luria; Daniel Birnbaum; Anna Sarkozy; Ying Hu; Hernan Gonorazky; Kristl Claeys; Himanshu Joshi; Adam Bournazos; Emily C Oates; Roula Ghaoui; Mark R Davis; Nigel G Laing; Ana Topf; Peter B Kang; Alan H Beggs; Kathryn N North; Volker Straub; James J Dowling; Francesco Muntoni; Nigel F Clarke; Sandra T Cooper; Carsten G Bönnemann; Daniel G MacArthur
Journal:  Sci Transl Med       Date:  2017-04-19       Impact factor: 17.956

Review 4.  Making sense of the limb-girdle muscular dystrophies.

Authors:  K M Bushby
Journal:  Brain       Date:  1999-08       Impact factor: 13.501

5.  A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield.

Authors:  Arunkanth Ankala; Cristina da Silva; Francesca Gualandi; Alessandra Ferlini; Lora J H Bean; Christin Collins; Alice K Tanner; Madhuri R Hegde
Journal:  Ann Neurol       Date:  2014-12-17       Impact factor: 10.422

6.  Multiple independent molecular etiology for limb-girdle muscular dystrophy type 2A patients from various geographical origins.

Authors:  I Richard; L Brenguier; P Dinçer; C Roudaut; B Bady; J M Burgunder; R Chemaly; C A Garcia; G Halaby; C E Jackson; D M Kurnit; G Lefranc; C Legum; J Loiselet; L Merlini; A Nivelon-Chevallier; E Ollagnon-Roman; G Restagno; H Topaloglu; J S Beckmann
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

7.  Characterization of novel CAPN3 isoforms in white blood cells: an alternative approach for limb-girdle muscular dystrophy 2A diagnosis.

Authors:  L Blázquez; M Azpitarte; A Sáenz; M Goicoechea; D Otaegui; X Ferrer; I Illa; E Gutierrez-Rivas; J J Vilchez; A López de Munain
Journal:  Neurogenetics       Date:  2008-06-19       Impact factor: 2.660

8.  Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A.

Authors:  I Richard; O Broux; V Allamand; F Fougerousse; N Chiannilkulchai; N Bourg; L Brenguier; C Devaud; P Pasturaud; C Roudaut
Journal:  Cell       Date:  1995-04-07       Impact factor: 41.582

9.  Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A.

Authors:  Emma J Groen; Richard Charlton; Rita Barresi; Louise V Anderson; Michelle Eagle; Judith Hudson; Mauro Santibanez Koref; Volker Straub; Katharine M D Bushby
Journal:  Brain       Date:  2007-12       Impact factor: 13.501

10.  Muscle MRI findings in patients with limb girdle muscular dystrophy with calpain 3 deficiency (LGMD2A) and early contractures.

Authors:  Eugenio Mercuri; Kate Bushby; Enzo Ricci; Daniel Birchall; Marika Pane; Maria Kinali; Joanna Allsop; Vincenzo Nigro; Amets Sáenz; Annachiara Nascimbeni; Luigi Fulizio; Corrado Angelini; Francesco Muntoni
Journal:  Neuromuscul Disord       Date:  2004-11-26       Impact factor: 4.296

View more
  2 in total

1.  Background splicing as a predictor of aberrant splicing in genetic disease.

Authors:  Alexieva D; Long Y; Sarkar R; Dhayan H; Bruet E; Winston Rm; Vorechovsky I; Castellano L; Dibb N J
Journal:  RNA Biol       Date:  2021-12-31       Impact factor: 4.652

2.  Integrated Genome and Transcriptome Sequencing to Solve a Neuromuscular Puzzle: Miyoshi Muscular Dystrophy and Early Onset Primary Dystonia in Siblings of the Same Family.

Authors:  Feng Zhu; Fengxiao Zhang; Lizhi Hu; Haowen Liu; Yahua Li
Journal:  Front Genet       Date:  2021-07-02       Impact factor: 4.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.